三种治疗原发性高血压降压药的成本-效果分析

摘要

Objective To conduct cost-effectiveness analysis for three commonly used antihypertensive drugs -Irvesrtan, Enalapril and Metoproloi. Methods 180 patients with primary hypertension in our hospital enrolled from January 2010 and January 2011 were randomly assigned to receive one of the three antihypertensive drugs -Irvesrtan, Enalapril and Metoproloi for 12 weeks. Then the cost-effectiveness analysis was done according to the treatment efficacy. Results The treatment efficacy of patients in Irbesartan or Enalapril group were superior to those in Metoprolol group [P ＜ 0. 05). In term of cost-effectiveness, Irbesartan was the best one among the three drugs. Conclusion Pharmacoeconomics is of great importance in the rational drug selection, increase of patients compliance and target- meeting rate, remarkable improvement of patients' qualify of life, and effective reduce of patients' disease burden for hypertensive patients.%目的 对常用的三种抗高血压药厄贝沙坦、依那普利、美托洛尔进行成本一效果分析.方法 选择2010年1月～2011年1月郴州市第一人民医院门诊高血压患者180例为研究对象,并随机分为三组,分别服用抗高血压药厄贝沙坦、依那普利、美托洛尔,疗程12周,根据疗效进行成本-效果分析.结果 厄贝沙坦、依那普利组疗效优于美托洛尔组(P<0.05);成本-效果分析,费用效果比最优为厄贝沙坦组.结论 药物经济学在为高血压患者合理选药、为患者提高依从性和控制达标率、显著改善患者的生存质量、有效降低疾病负担等方面具有重要意义.